Gavorestat is a small molecule commercialized by Applied Therapeutics, with a leading Pre-Registration program in Galactosemia. According to Globaldata, it is involved in 5 clinical trials, of which 3 were completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Gavorestat’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Gavorestat is expected to reach an annual total of $71 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Govorestat (AT-007) is under development for the treatment of galactosemia in both adult and pediatric patients, sorbitol dehydrogenase deficiency (SORD Deficiency) and PMM2-CDG, formerly known as congenital disorder of glycosylation type 1a. The drug candidate is administered through oral route in adult patients. It acts by targeting aldose reductase.
Applied Therapeutics Overview
Applied Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops transformative drugs in areas of Galactosemia and Diabetic Cardiomyopathy (DbCM). The company product pipeline includes include AT-001 a novel aldose reductase inhibitor, AT-007 a SORD Deficiency, AT-001 a Diabetic Peripheral Neuropathy. Applied Therapeutics also develops preclinical pipeline product AT-003, an ARI designed for the treatment of diabetic retinopathy and AT-104 a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukaemia. It serves customers throughout the US. Applied Therapeutics is headquartered in New York, the US.
The operating loss of the company was US$83 million in FY2022, compared to an operating loss of US$105.6 million in FY2021. The net loss of the company was US$82.5 million in FY2022, compared to a net loss of US$105.6 million in FY2021.
For a complete picture of Gavorestat’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.